Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Sequencing systemic therapies in advanced prostate cancer: spoiled for choice but not for evidence.

Jones RJ.

Eur Urol. 2014 Sep;66(3):466-7. doi: 10.1016/j.eururo.2013.12.053. No abstract available.

PMID:
24411282
2.

Prostate cancer: treatment sequencing for CRPC--what do we know?

Heidenreich A, Porres D.

Nat Rev Urol. 2014 Apr;11(4):189-90. doi: 10.1038/nrurol.2014.36. No abstract available.

PMID:
24595127
3.

One size does not fit all: can we choose the best sequence of treatment in asymptomatic castration-resistant prostate cancer patients?

Loriot Y, Massard C, Fizazi K.

Eur Urol. 2014 Oct;66(4):653-4. doi: 10.1016/j.eururo.2014.03.024. No abstract available.

PMID:
24735730
4.

Words of wisdom. Re: Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents.

Heemers HV, Mohler JL.

Eur Urol. 2014 Sep;66(3):597. doi: 10.1016/j.eururo.2014.06.032. No abstract available.

6.

Sequential treatment with taxanes and novel anti-androgenic compounds in castration-resistant prostate cancer.

Esch L, Schulz WA, Albers P.

Oncol Res Treat. 2014;37(9):492-8. doi: 10.1159/000365530. Review.

7.

Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.

Yasumizu Y, Miyajima A, Kosaka T, Miyazaki Y, Kikuchi E, Oya M.

J Urol. 2014 Jan;191(1):227-34. doi: 10.1016/j.juro.2013.07.101.

PMID:
23954373
8.

Urological cancer: Is docetaxel the 'black widow' of mCRPC drugs?

Liaw BC, Oh WK.

Nat Rev Clin Oncol. 2015 Jun;12(6):316-8. doi: 10.1038/nrclinonc.2015.79. No abstract available.

PMID:
25917253
9.

The MAINSAIL trial: an expected failure.

Boccardo F.

Lancet Oncol. 2015 Apr;16(4):355-6. doi: 10.1016/S1470-2045(15)70058-6. No abstract available.

PMID:
25743936
10.

Taxane mechanisms of action: potential implications for treatment sequencing in metastatic castration-resistant prostate cancer.

Fitzpatrick JM, de Wit R.

Eur Urol. 2014 Jun;65(6):1198-204. doi: 10.1016/j.eururo.2013.07.022. Review.

PMID:
23910941
11.

Dasatinib and docetaxel in advanced prostate cancer.

Lara PN Jr, Evans CP.

Lancet Oncol. 2013 Dec;14(13):1248-9. doi: 10.1016/S1470-2045(13)70500-X. No abstract available.

PMID:
24211164
12.

Analysis of docetaxel therapy in elderly (≥70 years) castration resistant prostate cancer patients enrolled in the Netherlands Prostate Study.

Gerritse FL, Meulenbeld HJ, Roodhart JM, van der Velden AM, Blaisse RJ, Smilde TJ, Erjavec Z, de Wit R, Los M; NePro Study Investigators..

Eur J Cancer. 2013 Oct;49(15):3176-83. doi: 10.1016/j.ejca.2013.06.008.

PMID:
23849828
13.

What is the appropriate use of palliative docetaxel in castration-resistant prostate cancer?

Steineck G, Glimelius B.

Acta Oncol. 2013 Nov;52(8):1589-92. doi: 10.3109/0284186X.2013.821206. No abstract available.

PMID:
24102178
14.
15.

Treatment options in castration-resistant prostate cancer: current therapies and emerging docetaxel-based regimens.

Saad F, Miller K.

Urol Oncol. 2014 Feb;32(2):70-9. doi: 10.1016/j.urolonc.2013.01.005.

PMID:
23506965
16.

The "artificial" docetaxel space: the evolving treatment paradigm of metastatic castration-resistant prostate cancer.

Orsola A, Bellmunt J.

Eur Urol. 2015 Jan;67(1):30-2. doi: 10.1016/j.eururo.2014.07.030. No abstract available.

PMID:
25108578
17.

Castration-resistant prostate cancer: where we stand in 2013 and what urologists should know.

Heidenreich A, Pfister D, Merseburger A, Bartsch G; German Working Group on Castration-Resistant Prostate Cancer (GWG-CRPC)..

Eur Urol. 2013 Aug;64(2):260-5. doi: 10.1016/j.eururo.2013.05.021. No abstract available.

PMID:
23706522
18.

Neutrophil-to-lymphocyte ratio predicts PSA response, but not outcomes in patients with castration-resistant prostate cancer treated with docetaxel.

Sümbül AT, Sezer A, Abalı H, Köse F, Gültepe I, Mertsoylu H, Muallaoğlu S, Özyılkan Ö.

Int Urol Nephrol. 2014 Aug;46(8):1531-5. doi: 10.1007/s11255-014-0664-7.

PMID:
24526335
19.

No clear evidence of a clinical benefit of a sequential therapy regimen with abiraterone acetate and enzalutamide.

Francini E, Petrioli R, Roviello G.

Expert Rev Anticancer Ther. 2014 Oct;14(10):1135-40. doi: 10.1586/14737140.2014.949677. Review.

PMID:
25135334
20.

Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.

Pond GR, Armstrong AJ, Galsky MD, Wood BA, Leopold L, Sonpavde G.

Urol Oncol. 2013 Nov;31(8):1457-63. doi: 10.1016/j.urolonc.2012.02.008.

PMID:
22552048
Items per page

Supplemental Content

Support Center